Summit Therapeutics plc Exercise Of Restricted Stock Units

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Exercise of Restricted Stock Units and Total Voting Rights 
 
   Oxford, UK, and Cambridge, MA, US, 24 April 2019 -- Summit Therapeutics 
plc (NASDAQ: SMMT, AIM: SUMM) announces the exercise by certain 
Non-Executive Directors of restricted stock units ('RSUs') that entitled 
the holder to subscribe for an ordinary share of one penny nominal value 
at a subscription price of one penny per ordinary share.  The RSUs were 
granted under the Company's 2017 Remuneration Policy and were eligible 
for exercise for a limited time after completion of a vesting period of 
one year. Details of the exercise of the RSUs, all of which took place 
on 23 April 2019, and which have been duly notified to the Company, are 
summarised below. 
 
 
 
 
Director          Position                 RSU's Exercised 
----------------  -----------------------  --------------- 
Frank Armstrong   Non-Executive Chairman            36,585 
----------------  -----------------------  --------------- 
Valerie Andrews   Non-Executive Director            17,073 
----------------  -----------------------  --------------- 
Dave Wurzer       Non-Executive Director            17,073 
----------------  -----------------------  --------------- 
Total                                               70,731 
-----------------------------------------  --------------- 
 
 
   Following the exercise of the RSUs, the shareholdings of all the 
Non-Executive Directors are as follows: 
 
 
 
 
                                            Shareholding     % of Issued Share 
Director             Position             (ordinary shares)       Capital 
-------------------  ------------------  ------------------  ----------------- 
                     Non-Executive 
Frank Armstrong       Chairman                     158,789*               0.1% 
-------------------  ------------------  ------------------  ----------------- 
                     Non-Executive 
Leopoldo Zambeletti   Director                       15,979              0.01% 
-------------------  ------------------  ------------------  ----------------- 
                     Non-Executive 
Valerie Andrews       Director                       66,196              0.04% 
-------------------  ------------------  ------------------  ----------------- 
                     Non-Executive 
Dave Wurzer           Director                       63,196              0.04% 
-------------------  ------------------  ------------------  ----------------- 
Total                                               304,160              0.19% 
---------------------------------------  ------------------  ----------------- 
 
 
   * Includes shares held by persons closely associated with the director 
 
   The Company also announces the exercise of a further 34,146 RSUs by 
former Non-Executive Directors of Summit. 
 
   Application has been made to the London Stock Exchange for the admission 
of 104,877 ordinary shares to trading on AIM and it is expected that 
admission will become effective and that dealings will commence at 8.00 
a.m. on or around 30 April 2019. 
 
   Total Voting Rights 
 
   Following the exercise of these RSUs, the total number of ordinary 
shares following admission will be 160,494,758 with each ordinary share 
carrying the right to one vote. The Company has no shares in Treasury; 
therefore following admission the total number of voting rights in 
Summit will be 160,494,758. This figure may be used by shareholders as 
the denominator for the calculations by which they will determine if 
they are required to notify an interest in, or change to their interest 
in, the share capital of the Company under the FCA's Disclosure and 
Transparency Rules. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Richard Pye (UK office)                            Tel:   [phone] 
Michelle Avery (US office)                                    [phone] 
 
Cairn Financial Advisers LLP (Nominated Adviser)   Tel:   [phone] 
Liam Murray / Tony Rawlinson 
 
 
 
   Notification of Transactions pursuant to Article 19(1) of Regulation 
(EU) No. 596/2014 
 
 
 
 
1   Details of the persons discharging managerial responsibilities/person 
     closely associated 
    ------------------------------------------------------------------------------------- 
a)  Name 
                              1.    Frank Armstrong 
 
                              2.    Valerie Andrews 
 
                              3.    Dave Wurzer 
    -----------------------  ------------------------------------------------------------ 
2   Reason for the notification 
    ------------------------------------------------------------------------------------- 
a)  Position / status 
                              1.    Non-Executive Chairman 
 
                              2.    Non-Executive Director 
 
                              3.    Non-Executive Director 
    -----------------------  ------------------------------------------------------------ 
b)  Initial notification /   Initial notification 
    Amendment 
    -----------------------  ------------------------------------------------------------ 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
    ------------------------------------------------------------------------------------- 
a)  Name                     Summit Therapeutics plc 
    -----------------------  ------------------------------------------------------------ 
b)  LEI                      213800NRW8AOMYMTBD89 
    -----------------------  ------------------------------------------------------------ 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
    ------------------------------------------------------------------------------------- 
a)  Description of the       Ordinary shares of 1 penny each 
    financial instrument, 
    type of instrument 
 
 
    Identification code      GB00BN40HZ01 
    -----------------------  ------------------------------------------------------------ 
b)  Nature of the            Exercise of restricted stock units (RSUs) to subscribe 
    transactions              for ordinary shares of one penny nominal value 
    -----------------------  ------------------------------------------------------------ 
c)  Price(s) and volume(s)     Price(s)                            Volume(s) 
    -----------------------    ----------------------------------  -------------------- 
                               (i)-(iii) 1p (exercise price) 
                                                                    1.    36,585 
 
 
                                                                    (ii)-(iii) 17,073 
    -----------------------    ----------------------------------  -------------------- 
 
d)  Aggregated information 
     - Aggregated volume       70,731 ordinary shares 
     - Price                   1 penny (exercise price) 
    -----------------------  ------------------------------------------------------------ 
e)  Date of the              23 April 2019 
    transactions 
    -----------------------  ------------------------------------------------------------ 
f)  Place of the             Outside a trading venue 
    transactions 
    -----------------------  ------------------------------------------------------------ 
 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

April 24, 2019 11:20 ET (15:20 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.